Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiichinkyo CoDSKYF -0.85%81 EV-to-EBIT is 18.35 as of Aug. 10, 2026, which is 42% below its 10-year median of 31.90. GuruFocus rates DSKYF with a GF Score™ of 81/100 and a GF Value™ of $32.67 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 683 Drug Manufacturers companies, Daiichinkyo Co ranks worse than 55.34% on this metric.
Daiichinkyo Co (OTCPK:DSKYF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Daiichinkyo Co's Enterprise Value for the quarter that ended in Jun. 2026 was $29,764 Mil.
Daiichinkyo Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,664 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiichinkyo Co EV-to-EBIT Related Terms
Daiichinkyo Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Daiichinkyo Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's EV-to-EBIT falls into.
Daiichinkyo Co's current Enterprise Value is $30,538 Mil.
Daiichinkyo Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,664 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiichinkyo Co (DSKYF) has a EV-to-EBIT of 18.35 as of Aug. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Daiichinkyo Co and its competitors. This is 42% below median its historical median of 31.90. Over the past decade, Daiichinkyo Co's EV-to-EBIT has ranged from 8.48 to 112.59. According to the industry distribution chart, Daiichinkyo Co ranks #378 out of 683 companies in the Drug Manufacturers industry, placing it in the top 55.3%.
Is Daiichinkyo Co's EV-to-EBIT too high?
Daiichinkyo Co's current EV-to-EBIT of 18.35 is 42% below median its 10-year median of 31.90. Over the past 10 years, this metric has ranged from a low of 8.48 to a high of 112.59. The Drug Manufacturers industry median EV-to-EBIT is 15.66. Daiichinkyo Co's value of 18.35 is 17.2% above this industry median. Based on the distribution chart, Daiichinkyo Co ranks #378 out of 683 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Daiichinkyo Co has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #378 out of 683 companies for EV-to-EBIT. This places Daiichinkyo Co in the lower half of its industry. The industry median EV-to-EBIT is 15.66. Daiichinkyo Co's value of 18.35 is 17.2% above this benchmark. Historically, Daiichinkyo Co's own EV-to-EBIT has ranged from 8.48 to 112.59 over the past decade. While the company's 10-year median is 31.90 vs. the industry median of 15.66, Daiichinkyo Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.66, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiichinkyo Co's current EV-to-EBIT of 18.35 is 17.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Daiichinkyo Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiichinkyo Co's current EV-to-EBIT is 18.35, which is 42% below median its own 10-year median of 31.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (DSKYF) is currently considered Significantly Undervalued. The stock's GF Value™ is $32.67, compared to a current price of $17.40 — trading 46.7% below its estimated fair value. The current EV-to-EBIT is 18.35, which is 42% below median its 10-year median of 31.90 and 17.2% above the Drug Manufacturers industry median of 15.66. Daiichinkyo Co's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Daiichinkyo Co (DSKYF), the current EV-to-EBIT is 18.35 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (DSKYF) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of $17.40 is trading 46.7% below its estimated GF Value™ of $32.67.
GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.
Key valuation signals for DSKYF:
EV-to-EBIT: 18.35 (42% below median its 10-year median of 31.90)
GF Value™: $32.67 vs. price of $17.40 (46.7% below fair value)
Industry Position: 17.2% above the Drug Manufacturers median (#378 of 683)
No single metric tells the full story. See the DSKYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
81GF Score
Get the complete analysis for DSKYF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DSKYF has been successfully added to your 
